Yahoo
NasdaqCM - Delayed Quote USD

PAVmed Inc. (PAVM)

2.0100 0.0000 (0.00%)
As of October 29 at 4:00:00 PM EDT. Market Open.
Chart Range Bar
Loading chart for PAVM
  • Previous Close 2.0100
  • Open 2.2000
  • Bid 2.3700 x 100
  • Ask 2.0600 x 100
  • Day's Range 2.0100 - 2.0100
  • 52 Week Range 1.8400 - 28.4400
  • Volume 282
  • Avg. Volume 29,951
  • Market Cap (intraday) 16.072M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -14.2000
  • Earnings Date Nov 13, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 36.50
  • Zacks Rating Neutral

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

www.pavmed.com

41

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PAVM
69.68%
S&P 500 (^GSPC)
11.13%

1-Year Return

PAVM
84.16%
S&P 500 (^GSPC)
11.51%

3-Year Return

PAVM
98.29%
S&P 500 (^GSPC)
82.57%

5-Year Return

PAVM
99.92%
S&P 500 (^GSPC)
65.19%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 33k
Earnings -5.48M
Profit Margin -16,603.03%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-6M
-4M
-2M
0
-120000.0%
-100000.0%
-80000.0%
-60000.0%
-40000.0%
-20000.0%

Analyst Insights

View More

Analyst Price Targets

16.00
36.50 Average
2.0100 Current
57.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/27/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 56 -> 57

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    15.75M

  • Enterprise Value

    17.14M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    44.49

  • Price/Book (mrq)

    0.49

  • Enterprise Value/Revenue

    153.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -39.69%

  • Return on Equity (ttm)

    -64.78%

  • Revenue (ttm)

    112k

  • Net Income Avi to Common (ttm)

    -20.63M

  • Diluted EPS (ttm)

    -14.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.07M

  • Total Debt/Equity (mrq)

    88.40%

  • Levered Free Cash Flow (ttm)

    -11.93M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.0100 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: